Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jade Biosciences, Inc. - Common Stock (NQ:JBIO)

14.65 -0.67 (-4.37%)
Streaming Delayed Price Updated: 10:04 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,471
Open 15.31
Bid (Size) 14.64 (100)
Ask (Size) 14.91 (100)
Prev. Close 15.32
Today's Range 14.64 - 15.36
52wk Range 6.565 - 17.71
Shares Outstanding 28,985,019
Dividend Yield 16.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces $45 Million Private Placement
From Jade Biosciences
Via GlobeNewswire

Performance

YTD
+3.5%
+3.5%
1 Month
+8.3%
+8.3%
3 Month
+57.9%
+57.9%
6 Month
+98.0%
+98.0%
1 Year
+44.5%
+44.5%

More News

Read More
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces $135 Million Private Placement
From Jade Biosciences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Posts Wider Loss in Q2 ↗
Via The Motley Fool
News headline image
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Jade Biosciences to Participate in Two Upcoming Investor Conferences
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
From Jade Biosciences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
From Jade Biosciences
Via GlobeNewswire
News headline image
Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Jade Biosciences, Inc. - Common Stock publicly traded?
Yes, Jade Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Jade Biosciences, Inc. - Common Stock trade on?
Jade Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jade Biosciences, Inc. - Common Stock?
The ticker symbol for Jade Biosciences, Inc. - Common Stock is JBIO on the Nasdaq Stock Market
What is the current price of Jade Biosciences, Inc. - Common Stock?
The current price of Jade Biosciences, Inc. - Common Stock is 14.65
When was Jade Biosciences, Inc. - Common Stock last traded?
The last trade of Jade Biosciences, Inc. - Common Stock was at 02/09/26 10:04 AM ET
What is the market capitalization of Jade Biosciences, Inc. - Common Stock?
The market capitalization of Jade Biosciences, Inc. - Common Stock is 424.63M
How many shares of Jade Biosciences, Inc. - Common Stock are outstanding?
Jade Biosciences, Inc. - Common Stock has 425M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.